Telix Pharmaceuticals Limited Research and Development Expense
Telix Pharmaceuticals Limited (TLPPF) reported Research and Development Expense of $171.25 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-02-20.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:ResearchAndDevelopmentExpense · last filed 2026-02-20
AUD
| Period end | Research And Development Expense 12 month |
|---|---|
| 2024-12-31 | 194.64M AUD 20-F · filed 2025-02-24 |
| 2023-12-31 | 128.54M AUD 20-F · filed 2025-02-24 |
| 2022-12-31 | 80.69M AUD 20-F · filed 2025-02-24 |
USD
| Period end | Research And Development Expense 12 month |
|---|---|
| 2025-12-31 | $171.25M 20-F · filed 2026-02-20 |
| 2024-12-31 | $127.93M 20-F · filed 2026-02-20 |
| 2023-12-31 | $85.31M 20-F · filed 2026-02-20 |